anti-melanoma mab fragments
Various (V09)Various (V09) compound in Syndax Pharmaceuticals's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
pharma · Acute Myeloid Leukemias · Breast Cancer
Syndax Pharmaceuticals
Syndax Pharmaceuticals drug portfolio — 29 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
730 3rd Ave, Floor 9, New York, NY 10017, US HQ
325 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 730 3rd Ave, Floor 9, New York, NY 10017, US
- Employees
- 325
- Programs
- 47
- Drugs
- 29
- Patents
- 6
Syndax Pharmaceuticals pipeline
Portfolio lens on 29 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Syndax Pharmaceuticals drug portfolio — 29 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to Syndax Pharmaceuticals in public FDA and regional records. Molecular target: Macrophage colony-stimulating factor 1 receptor.
- Target
- Macrophage colony-stimulating factor 1 receptor
- Mechanism
- Macrophage colony stimulating factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Macrophage colony-stimulating factor 1 receptor.
- Target
- Macrophage colony-stimulating factor 1 receptor
- Mechanism
- Macrophage colony stimulating factor receptor inhibitor
-
azacitidine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
- Target
- DNA (cytosine-5)-methyltransferase 1
- Mechanism
- DNA (cytosine-5)-methyltransferase 3A inhibitor
-
blinatumomab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD19.
- Target
- B-lymphocyte antigen CD19
- Mechanism
- T cell surface glycoprotein CD3 cross-linking agent
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Syndax Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Syndax Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Syndax Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Syndax Pharmaceuticals in public FDA and regional records.
-
cytarabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
daunorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Syndax Pharmaceuticals's portfolio. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to Syndax Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
fulvestrant
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor antagonist
-
Development asset linked to Syndax Pharmaceuticals in public FDA and regional records. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Syndax Pharmaceuticals in public FDA and regional records.
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Syndax Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Menin.
- Target
- Menin
- Mechanism
- Menin inhibitor
-
Development asset linked to Syndax Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Syndax Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Syndax Pharmaceuticals in public FDA and regional records.
-
venetoclax
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Apoptosis regulator Bcl-2.
- Target
- Apoptosis regulator Bcl-2
- Mechanism
- Apoptosis regulator Bcl-2 inhibitor